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Background: Decisions about systemic treatment of women with metastatic breast cancer are often based on
estrogen receptor (ER), progesterone receptor (PgR), and Her2 status of the primary tumor. This study prospectively
investigated concordance in receptor status between primary tumor and distant metastases and assessed the impact
of any discordance on patient management.
Materials and methods: Biopsies of suspected metastatic lesions were obtained from patients and analyzed
for ER/PgR and Her2. Receptor status was compared for metastases and primary tumors. Questionnaires were
completed by the oncologist before and after biopsy to determine whether the biopsy results changed the
treatment plan.
Results: Forty women were enrolled; 35 of them underwent biopsy, yielding 29 samples sufﬁcient for analysis; 3/29
biopsies (10%) showed benign disease. Changes in hormone receptor status were observed in 40% (P = 0.003) and
in Her2 status in 8% of women. Biopsy results led to a change of management in 20% of patients (P = 0.002).
Conclusions: This prospective study demonstrates the presence of substantial discordance in receptor status
between primary tumor and metastases, which led to altered management in 20% of cases. Tissue conﬁrmation
should be considered in patients with clinical or radiological suspicion of metastatic recurrence.
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introduction
The diagnosis of metastatic breast cancer is usually made by
a combination of clinical signs and symptoms and by
radiological evaluation. Conﬁrmatory biopsy of suspected
metastatic lesions is rarely carried out at most centers, even if
many years have passed since diagnosis of primary breast
cancer. Systemic management of metastatic breast cancer with
endocrine therapy, chemotherapy, or biologic agents (such as
trastuzumab or lapatinib) is therefore based usually on tumor
characteristics from the patient’s original breast surgery.
However, certain characteristics such as estrogen receptor (ER),
progesterone receptor (PgR), and Her2 status may change with
recurrent disease. Retrospective reviews have shown
discordance between ER and PgR status between the primary
tumor and metastases in 15%–40% of women [1–18] and
7%–26% for Her2 status [19–21]. Therefore, it is possible that
many patients with metastatic disease might be offered
suboptimal therapy.
Previous studies of discordance in hormone receptor and
Her2 status between primary tumor and metastases have
limitations. Most were retrospective [8, 17], used older
pathological techniques [1–6], utilized different staining
procedures between primary tumor and metastases [22], or
included heterogeneous groups of patients including those
with local recurrences [14, 17, 23, 24]. In addition,
retrospective reviews have inherent selection biases such that
patients may have been selected for biopsy based on suspicion
of other pathological abnormality, atypical presentation of
metastases, prolonged time from primary disease, or the
perceived ease and acceptability of performing a biopsy
[25]. Also, the impact of the biopsy results on clinical
management cannot be captured from retrospective reviews.
Finally, prior studies have not been able to provide
information about the feasibility of a biopsy procedure or its
acceptability to patients.
The primary objective of the present study was to
prospectively evaluate possible changes that occur in ER, PgR,
and Her2 status between primary tumor and distant metastases
before initiation of therapy. Secondary objectives were to
determine whether any discordance between primary disease
and metastases altered patient management and to demonstrate
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materials and methods
study design
This prospective cohort study took place in a single institution with a large
breast medical oncology practice and accrued patients over a 1-year period
from September 2006 to October 2007. Patients were identiﬁed at the time of
suspected clinical or radiological recurrence by their primary oncologist.
Patients were excluded if they had operable breast or axillary recurrence with
no evidence of metastatic disease or if they had already started on therapy for
metastatic disease. Patients were also excluded if the location of the lesion was
not amenable to biopsy by the following criteria: rib lesion, brain metastases,
lesion <1 cm in size, or lesion in a location that could not be reached by core
biopsy techniques available with interventional radiology. Further exclusion
criteria included an international normalized ratio or partial thromboplastin
time above the upper limit of normal for our institution.
Patients who met all eligibility criteria were provided with written
information about the study. The proportion of patients approached who
provided written informed consent for this study was collected as
a surrogate marker of acceptability of a biopsy procedure. Reasons for
declining to participate were documented. The proportion of patients who
consented to biopsy but for whom a biopsy was subsequently not feasible
was recorded as a surrogate marker of feasibility of obtaining biopsies.
The study was approved by the research ethics board at the University
Health Network, Toronto, Canada.
Consenting patients underwent core biopsy by an interventional
radiologist, ﬁne needle aspirate by a diagnostic pathologist, or drainage
of pleural ﬂuid by ultrasound guidance in a dedicated procedure clinic. An
interventional radiologist reviewed X-rays or scans of suspicious lesions and
appropriateness for biopsy was determined by anatomic location of the
lesion. In patients with multiple lesions, the lesion in the safest and most
practical location was chosen for biopsy. Biopsy samples were ﬁxed in
formalin and parafﬁn embedded before analysis. Core biopsy specimens
from bone metastases were not decalciﬁed, in order to ensure that
interpretation of ER and PgR was not compromised. Samples were analyzed
pathologically to conﬁrm metastatic disease and secondly to evaluate ER
and PgR by immunohistochemistry (IHC; Ventana 6F11 and Ventana clone
16, respectively) and Her2 status by FISH.
The assessment of ER, PgR, and Her2 for the metastatic tissue was then
compared with that for the primary tumor. The pathologist analyzing the
samples was blinded as to the patients’ original hormone receptor and
Her2 status. Further, primary samples were reassessed to conﬁrm the
original hormone receptor status and Her2 status. There were no
signiﬁcant changes on reassessment of the primary tumor. For samples
that previously had not reported percentage of cells staining for ER and
PgR, this was recorded at the time of reassessment. The threshold
values for reporting positivity were 10% for ER and PgR as per local
institutional guidelines. As mentioned, the percentage of cells expressing
ER and PgR was reported for both the primary tumor and the metastasis.
For Her2 evaluation, FISH was employed for all metastatic samples due
to the high rate of false positivity when IHC is completed on core biopsy
samples due to edge artifact [26, 27].
The primary oncologist caring for the patient completed a questionnaire
both before and after the biopsy to assess if a change in management had
occurred and if the change was related to the biopsy results. In order to
assess patient acceptance and feasibility of carrying out a biopsy, patients
completed a questionnaire at the end of the study and were also asked if
they perceived a delay in initiation of their treatment due to the time
required to obtain a biopsy.
Information about adjuvant therapy (if any) received by each patient and
time between initial diagnosis and metastatic presentation were also
documented.
statistical methods
To fulﬁll the primary objective of determining the probability of
discordance in receptor status, 27 paired samples were required to
detect a discordance rate of ‡20% with 80% power using a one-sided alpha
of 5%. For the secondary objective of determining effect on treatment, if we
assume that 90% of the time oncologists treat women with metastatic breast
cancer based on the characteristics of the primary tumor and that a change
in treatment of 20% of patients is clinically signiﬁcant, a sample size of
27 was also adequate (under the same null hypothesis as above). The sample
size was subsequently increased to 35 to allow for treatment driven by
patient wishes and to allow for 10% of cases where a biopsy may not be
feasible and 5% rate of patient withdrawal from the study. Data were
analyzed using Stata statistical software version 10.0; McNemar’s test or
Fisher’s exact test was used where appropriate.
role of funding source
The sponsor of this study had no role in the study design, data collection,
data analysis, data interpretation, or writing of the report. The primary and
corresponding authors had access to all data in the study and were
responsible for submission of this paper for publication.
results
participants
Forty-nine patients were approached for this study. Of these,
nine patients declined participation for the following reasons
(in decreasing frequency): advised not to participate by
another physician, language barrier to understanding and
obtaining informed consent, fear of biopsy causing tumor
spread, and participation in another clinical trial that did not
allow enrollment. Forty patients (82%) provided written
informed consent to participate. Of these, three patients were
found after initial screening to have metastatic lesions not
amenable to biopsy due to location. A further two patients
were found on subsequent radiological investigation in
preparation for biopsy to have complete resolution of their
initial suspected metastatic lesion. Thirty-ﬁve patients had
biopsy of their metastatic lesions, from which 29 analyzable
samples were obtained (Figure 1).
characteristics of patients
Of the women recruited to the study, 61% had received
adjuvant chemotherapy, 53% had received endocrine therapy,
and 2% had received trastuzumab; 26% were still receiving
endocrine therapy when metastases were diagnosed. Median
duration between diagnosis of the primary tumor and
identiﬁcation of a metastatic lesion was 2.4 years (interquartile
range 1.2–6.5 years). All patients underwent biopsy before
receiving any treatment of metastatic disease. The sites of
metastases biopsied are described in Table 1; most were from
bone, the most common site of metastasis from breast cancer.
comparison of receptor status between primary
and metastatic lesion
Of the 29 analyzable samples, three diagnosed as benign disease
(two bone biopsies and one cerebrospinal ﬂuid) and one sample
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up, these women all remain free of breast cancer recurrence at
1 year. The remaining 25 samples provided histological
conﬁrmation of metastatic breast cancer. Based on the primary
tumor, 16 of 25 patients were ER+, 9 of 25 patients were PgR+,
and 4 of 25 patients were Her2+ based on original report. The
primary tumour slides for these 25 patients were reassessed to
conﬁrm and quantify ER and PgR status. Of the 25 paired
samplesfromprimaryandmetastaticlesions,10werediscordant
for ER/PgR and two were discordant for Her2 (Figure 2), with
a complete change in receptor status. This resulted in a 40%
overall discordance rate for ER and PgR (P = 0.026) and an 8%
discordance rate for Her2. All changes in hormone receptor
statusinvolvedacompletelossofER,PgR,orboth.Bothchanges
in Her2 status involved a complete gain in Her2 overexpression
compared with the primary tumor.
The percentage of cells expressing ERs and/or PgRs for the
paired samples is presented in Figure 2. A change in ER or PgR
status was reported if quantitative staining changed from
negative (<5%) to positive (>10%) or vice versa. Three
patients had an increase in percentage positivity of ER from
primary to metastatic lesion of ‡10%, but none of these
resulted in a complete gain in ER status. Five patients had
a quantitative decrease in expression of ER positivity
between primary tumor and metastasis, of whom three
became ER negative by the above deﬁnition. Almost all the
tumors that were positive for PgR in the primary had
some loss of PgR in the metastatic lesion, ranging from 15%
to 90% absolute decrease in number of cells with PgR
expression (Figure 2B). Only one patient had an increase
in percent positivity of PgR from 10% to 100% in
a metastasis. All the tumors that were triple negative in the
primary tumor (n = 6) did not change on analysis of the
metastatic lesion.
changes in clinical management
Six independent medical oncologists accrued patients to this
study. Of the 29 patients who underwent biopsy, 20% (6 of 29)
had a change in their treatment plan based on the results of the
Table 1. Baseline information of all patients who underwent biopsy
attempt
n (%)
Histology primary disease (n = 35)
Inﬁltrating ductal 28 (80)
Inﬁltrating lobular 5 (14)
Mixed lobular and ductal 1 (3)
DCIS with microinvasion 1 (3)
Stage at diagnosis (N = 35)
1 6 (17)
2a 5 (14)
2b 8 (23)
3a 9 (26)
3b 3 (10)
3c 4 (11)
Hormone status primary (n = 35)
ER+/PgR+ 13 (37)
ER+/PgR2 10 (29)
ER2/PgR2 12 (34)
ER2/PgR+ 0
Her2 status primary (n = 35)
Her2+ 13 (37)
Her22 22 (63)
Sites of biopsy (n = 29)
Bone 11 (38)
Soft tissue (not surgically curable) 10 (34)
Pleural effusion 3 (10)
Liver 3 (10)
Lung 1 (3)
CSF 1 (3)
DCIS, ductal carcinoma in situ; ER, estrogen receptor; PgR, progesterone
receptor; CSF, cerebrospinal ﬂuid.
49 approached
9 refused*
-2 patient specific reasons
-4 physician advised
-2 language barrier
-1 participating in another study
40 agreed
5 not feasible
-3 location
-2 lesion disappeared  
35 biopsies completed
6 insufficient sample
29 samples 
29 samples
3 benign, 1 lymphoma 25 breast cancer metastases
10  discordant with primary  15 concordant with primary
3 loss ER
7 loss PR
2 gain of Her2
B
A
Figure 1. (A) Organization chart of participants. (B) Organization chart of results.
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of metastatic breast cancer on biopsy, not only did their
treatment plan change but also the biopsy results drastically
changed their prognosis. A gain in Her2 overexpression
resulted in change of management for two patients, both of
whom qualiﬁed for trastuzumab or for a clinical trial, based on
the result of the biopsy.
patient acceptance
Forty patients consented over a period of just >1 year. For the
patients who underwent biopsy, 38% reported some anxiety
before the procedure. Pain associated with the biopsy was
reported by 48% of women, with 28% reporting pain as mild
and 20% as moderate. No patient reported pain as severe. Of
those who experienced pain, 25% reported that the pain lasted
for >1 day after the biopsy. Overall, patients were satisﬁed with
the biopsy procedure. The main concern expressed by patients
was the time required to obtain the biopsy. Most women
underwent a biopsy within 2 weeks of consenting to the study,
but treatment was delayed in two patients by 30 days due to
scheduling of the biopsy procedure. For patients who
underwent a biopsy that did not result in a change in
management, they reported reassurance at having tissue
conﬁrmation of metastatic disease.
discussion
Changes in molecular markers in women with breast cancer
between primary lesion and metastatic disease are increasingly
important because of increasing use of targeted therapies [28,
29]. While previous retrospective studies have indicated that
change in receptor status may occur, we are unaware of prior
prospective studies to evaluate discordance between primary
and metastatic lesions.
This current study demonstrated 40% discordance in
ER/PgR status and 8% discordance in Her2 status in a cohort
of patients who presented with new lesions suspicious for
metastatic breast cancer. The rate of ER and PgR discordance is
similar if not higher than that reported in previous
retrospective reviews, and all changes involved a loss in receptor
status. While interlaboratory variability may occur with IHC
assessment [30], in the present study, all samples (primary
tumor and metastases) were reviewed centrally with the same
staining technique to reduce interlaboratory variability.
Additionally, the observed changes were veriﬁed by a single
(blinded) pathologist, further decreasing interobserver
variability. This is in contrast to prior retrospective studies
which in large part relied on information gained from
pathology reports alone, prepared by a number of different
pathologists [22, 24, 30]. In addition, all Her2 analysis was
carried out with FISH, unlike prior retrospective studies which
for the most part relied on IHC quantiﬁcation of Her2
overexpression [22–24]. The problem with relying on IHC for
core biopsy specimens is that a high rate of false-positive Her2
overexpression may be reported due to edge artifact [26, 27].
Potential mechanisms for the observed discordance between
primary tumor and metastases may include either treatment-
induced selection or progression of tumor cells to a more
malignant phenotype. Selective killing of ER+ and PgR+ tumor
cells by adjuvant hormonal treatment might result in selection
of untreated or undertreated ER2 and PgR2 cells, with which
time may lead to metastatic recurrence [31]. Also, molecular
changes may result in decreased expression or complete loss of
hormone receptors or an increase in expression of Her2,
leading to a more aggressive phenotype.
In the present study, we have linked changes in ER/PgR and
Her2 status with impact on management. Based on the biopsy
results, 20% of patients had a signiﬁcant change in
management. For four of these patients in whom the biopsy
was either benign or another cancer, the biopsy results changed
their diagnosis, prognosis, and life expectancy. While one might
expect that the 10 patients who had a change in receptor status
would have had a change in management, only six of them had
a change in management plan. Reasons for this were
a combination of patient wishes, physician practice/acceptance
of results, and other tumor characteristics.
Clinicians are often reluctant to request a biopsy from
a patient perhaps due to their belief that she may experience
discomfort or inconvenience at a time when she has just been
informed that she has metastatic disease. In this study, we
demonstrated that patients were motivated to undergo biopsy
to conﬁrm their metastases, and even where the biopsy did not
affect management, they reported reassurance in having tissue
conﬁrmation of their disease. Accrual to this study was faster
than expected, and anxiety and discomfort associated with
obtaining a tissue biopsy was mild to moderate.
The results of this study are generalizable to other women
with an initial diagnosis of metastatic breast cancer as most
biopsies were obtained from bone lesions and (unlike prior
retrospective studies) local recurrences were excluded. We have
studied the population for whom a change in receptor status
would have the most clinical signiﬁcance. All patients in this
prospective study were assessed before receiving any therapy for
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Figure 2. (A) Percentage change in positivity of estrogen receptor (ER).
(B) Percentage change in positivity of progesterone receptor (PgR).
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molecular markers in the absence of new therapy but also
demonstration of the clinical signiﬁcance of obtaining
a conﬁrmatory biopsy. A limitation of the study is its relatively
small size such that any subgroup analysis would be unreliable:
it does not allow for changes to be related to type of adjuvant
treatment, location of metastases, or disease-free interval.
Our study has implications for the design of clinical trials
that evaluate targeted therapies. Mandating a biopsy of
metastases at study entry would ensure that the target is
expressed and would allow for a more efﬁcient study to be
carried out.
In summary, this prospective study has demonstrated
a substantial rate of discordance in pathology and molecular
markers between primary and suspected metastatic lesions in
women with breast cancer that is sufﬁcient to alter
management in 20% of them. Tissue conﬁrmation should be
considered standard of care in patients with clinical and/or
radiological suspicion of metastatic recurrence and lesions
amenable to biopsy.
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